Sessa Capital’s AnaptysBio ANAB Stock Holding History

Sessa Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-166,700	Closed	-$3.58M	–	30
2020 Q4	$3.58M	Sell	166,700 -360,704	-68%	-$8.76M	0.23%	22
2020 Q3	$7.78M	Hold	527,404	–	–	0.63%	21
2020 Q2	$11.8M	Hold	527,404	–	–	1.18%	14
2020 Q1	$7.45M	Buy	527,404 +377,404	+252%	+$5.72M	0.91%	11
2019 Q4	$2.44M	Buy	+150,000	New	+$3.55M	0.25%	20

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sessa Capital's ANAB Position: Q1 2021 in Review

Sessa Capital sold out of AnaptysBio (ANAB) in Q1 2021, closing a stake of 166,700 shares — an estimated $3.58M sold.

Sessa Capital first reported a position in ANAB in Q4 2019 and held it in 5 quarters. The position peaked at $11.8M in Q2 2020. 122 funds tracked by Wall St. Rank hold ANAB as of Q1 2021.

Sessa Capital reported no remaining AnaptysBio position as of Q1 2021 after selling out during the quarter.
Sessa Capital sold 166,700 AnaptysBio shares in Q1 2021, an estimated $3.58M.
Sessa Capital first reported a position in AnaptysBio in Q4 2019 and held it in 5 quarters.
Sessa Capital's AnaptysBio position peaked at $11.8M in Q2 2020.
122 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2021.

Based on Sessa Capital's 13F filing for Q1 2021, filed 17 May 2021.